tests, yet little information is available on treatment of pain in these patients.
Due to their potency and rapid onset of action, opioids are a mainstay of analgesic therapy, especially for acute pain. Opioid use was once limited in horses primarily due to concern over opioid-induced excitement or slowed gastrointestinal (GI) motility (Clutton, 2010; Sanchez & Robertson, 2014) , but opioids are now commonly used to treat pain in this species (Clutton, 2010; Sanchez & Robertson, 2014; Sellon, Roberts, Blikslager, Ulibarri, & Papich, 2004; Love, Lane, & Murison, 2006; Taylor, et al., 2016) . One drawback of opioids is a relatively short duration of action. For example, butorphanol, the most commonly used opioid in horses, provides nociception from a thermal stimulus (Love, Taylor, Murrell, & Whay, 2012) or elective surgical procedure (Taylor, et al., 2016) for an average of only 3 hr. This makes frequent dosing or delivery by infusion necessary for control of pain of even moderate duration. However, buprenorphine, a newer opioid, is measurable in the plasma for up to 24 hr in some horses (Davis, Messenger, LaFevers, Barlow, & Posner, 2012; Messenger, Davis, LaFevers, Barlow, & Posner, 2011) and has an antinociceptive duration of 6-12 hr in adult horses undergoing surgical procedures (Taylor, et al., 2016; Love, Taylor, Murrell, & Whay, 2012; Love, Pelligand, Taylor, Murrell, & Sear, 2015) . Although buprenorphine can cause opioid-mediated adverse behavioral effects when administered alone to nonpainful adult horses (Carregaro, Luna, Mataqueiro, & de Queiroz-Neto, 2007; Carregaro, Neto, Beier, & Luna, 2006; Davis et al., 2012; Messenger et al., 2011) , these effects appear to be minimal in painful foals (Risberg et al., 2015) .
In addition to the long duration of action, buprenorphine is attractive for clinical use because it is systemically absorbed after sublingual (SL) or oral transmucosal administration. This has been demonstrated in multiple species (Robertson, Taylor, Bloomfield, & Sear, 2002; Robertson, Taylor, & Sear, 2003; Robertson, Lascelles, Taylor, & Sear, 2005; Porters et al., 2015; Krotscheck, Boothe, Little, & Erb, 2010; . McInnes et al., 2008; Hedges, Pypendop, Shilo-Benjamini, Stanley, & Ilkiw, 2014; Kuhlman, Lalani, Magluilo, Levine, & Darwin, 1996; Gulledge, Messenger, Cornell, Lindell, & Schmiedt, 2017; Doodnaught et al., 2017; Abbo et al., 2008) , including adult horses (Messenger et al., 2011) , although more recent studies indicate that the sampling site used in some of these studies may have overestimated the amount of drug absorbed Messenger et al., 2011) . Sublingual administration of drugs has several advantages, including the need for only minimal restraint during drug delivery and elimination of painful injections.
Buprenorphine has been used clinically in foals. It has been shown to provide analgesia when administered IM to neonatal foals (Risberg et al., 2015) and sublingually to one 5-month-old filly (Walker, 2007) . However, there are no pharmacokinetic studies of buprenorphine administered by any route to neonatal foals.
When compared to adult horses, neonatal foals have a higher basal metabolic rate, a larger percentage of total body water, and a more permeable blood-brain barrier, causing differences in pharmacokinetics and pharmacodynamics of drugs between horses in these two age categories (Baggot, 1994) . Butorphanol pharmacokinetics and pharmacodynamics are different between adult horses and foals (Arguedas, Hines, Papich, Farnsworth, & Sellon, 2008) . Therefore, dose recommendations for adults, including recommendations for opioids, should not be assumed safe and effective for neonates.
The plasma concentration of buprenorphine that would provide analgesia is unknown in horses. The predicted analgesic plasma concentration ranges from 0.6 ng/ml in dogs (Ko et al., 2011) and 0.7 ng/ml sheep (Nolan, Livingston, & Waterman, 1987) to 1 ng/ml in humans (Watson, McQuay, Bullingham, Allen, & Moore, 1982) . For this study, 0.6 ng/ml was used as the presumed analgesic threshold.
The objectives of this study were to administer buprenorphine SL and IV to neonatal foals and to determine: (a) plasma drug concentrations and pharmacokinetic profiles of buprenorphine; (b) drug effects on physiologic parameters; and (c) drug effects on behavioral parameters using time spent in various activities (time activity budgets). Our hypothesis was that buprenorphine administered SL or IV to neonatal foals would result in plasma drug concentrations above a predicted therapeutic value extrapolated from other species (>0.6 ng/ml) for more than 6 hr without significant adverse physiologic, activity, or behavioral effects.
| MATERIAL S AND ME THODS
Six healthy Arabian or Arabian-pony cross foals <21 days of age and of both sexes (three female, three male), deemed pain-free and healthy by physical exam and assessment of passive transfer of maternal antibody, were enrolled in a blinded, randomized, 3-period, 5-sequence, 3-treatment crossover prospective study. The study was approved by the Institutional Animal Care and Use Committee at Washington State University.
All foals started the study at 1-2 days of age and received three treatments: (a) buprenorphine (Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA) administered IV and saline SL (group IV), (b) buprenorphine SL and saline IV (group SL), and (c) saline administered via both routes as a control (group C). Personnel administering drugs and collecting data were blinded to the treatments. The foals were randomized to one of five sequences of treatments using a random number generator (https://www.random.org/. Randomness and Integrity Services Ltd; Dublin Ireland). There was a minimum five-day washout period between treatments of the same foal. Initial dosing was 0.01 mg/kg buprenorphine IV and SL. The samples from the first foals dosed via each route were analyzed as soon as possible to determine dosing adequacy. Based on the low plasma concentrations in these foals and the short detection time after dosing, the decision was prepared to dose all remaining foals at 0.02 mg/kg. In total, two foals received 0.01 mg/ kg IV and four foals received 0.02 mg/kg IV while one foal received 0.01 mg/kg SL and five foals received 0.02 mg/kg SL.
On the day prior to each treatment, the foal, which had previously had only minimal handling, and its dam were placed in a box stall at the research facility. The mares were allowed free access to grass hay and water, and the foals were allowed to nurse their dams ad libitum. On the morning of the experiment, baseline physiologic data (heart rate, respiratory rate, temperature, fourquadrant GI sounds, mucous membrane color, and capillary refill time) were recorded prior to instrumenting the foal. Respiratory rate was counted by visual observation from outside the stall without disturbing the foal. Foals were gently restrained in their stalls and heart rate determined by cardiac auscultation; rectal temperature was measured with a digital thermometer; GI sounds were evaluated by auscultation of the dorsal and ventral quadrants on both sides of the abdomen and scored as previously described (Arguedas et al., 2008) . Briefly, each quadrant was ausculted for Intravenous treatments were administered through the jugular catheter and that catheter was removed immediately after treatment. Sublingual treatments were administered by gently restraining the foal and depositing the treatment under or alongside the tongue over 5-10 s. Blood samples were collected from the cephalic vein catheter prior to drug administration (time 0) and 10, 20, 30, and 45 min and 1, 1.5, 2, 4, 6, 8, 12 , and 24 hr posttreatment. Prior to each sample collection, 4 ml of blood was collected and discarded to eliminate stagnant blood and flush solution in the catheter. Four mls of blood were then collected, and the catheter was flushed with 5 ml heparinized saline.
Samples were placed into lithium heparin tubes and stored on ice until centrifugation at 2,000 g for 10 min could be performed (<60 min). The plasma was separated and stored in cryotubes at −80°C until analysis by ultra-performance liquid chromatography with mass spectrometry.
Physiologic data (heart rate, respiratory rate, body temperature, GI sounds, mucous membrane color, and capillary refill time) were recorded as described above at the same time points that blood samples were collected. The foals were continuously monitored for signs of abdominal pain (rolling, flank watching, excessive pawing, extending forelegs forward and rear legs backward [parking out]), excitement, or sedation. In addition, foals were continuously videoed for the first 4 hr after treatment. The video camera was mounted above the stall to provide the largest visual field without interfering with the foal's normal behavior. Following completion of the study, the videos were watched by 3-blinded, trained observers and the amount of time spent in different activities (nursing, active behaviors, inactive behaviors, and recumbency; Table 1) were documented similarly to a previous study (Arguedas et al., 2008) . Each activity was recorded as a percentage of time spent in that activity (i.e., "time budget") within each hour following treatment administration and over the total 4-hr observation period. Activity documentation was stopped whenever
Behavior Description
Nursing Foal is actively nursing or trying to nurse (searching the udder, following the udder when dam moves away, head bumping the udder); cessation of nursing for ≤10 s to change sides or lick lips is included
Active behaviors
Walking forwards or backwards; jumping, trotting, or kicking; cessation of nursing for >10 s to lick lips or walk; pawing the ground; chewing/eating hay, shavings, or manure; drinking water or licking any object (walls, dam, etc.); investigating any object (floor, walls, feeder, etc.) while standing or moving; Rubbing any part of the body against the side of the stall, dam, or front leg; scratching the flank with teeth or scratching the head with a hind leg; shaking the whole body; stretching (hyperextension of the hind legs or hyperflexion of the head and neck); urinating/defecating.
Inactive behaviors
Standing with head above, at or below withers but performing none of the active behaviors; stepping slowly, forward or backward but performing none of the active behaviors; standing and having cyclic periods of dozing (progressive body relaxation with lowering of the head and partial or total loss of body balance).
Recumbent
Foal in sternal or lateral recumbency.
Data collection
Investigators are in the stall collecting data.
Stop
Foal is completely out of the camera's visual field or is partially out so that its behavior cannot be accurately characterized.
TA B L E 1 Description of specific behaviors for analysis of video recordings of neonatal foals following treatment with 0.01 or 0.02 mg/kg buprenorphine (IV or sublingual) or saline the foal was out of camera view, and this time was not included in the total time percentage. Activity documentation was also stopped during the eight data collection periods, and the response to humans (Average Data Collection Score; ADCS) was determined during this time by observations of three behaviors: response to (a) human approach, (b) human contact/restraint, and (c) release (Table 2) . This system was reported in a previous study (Arguedas et al., 2008) . The number of steps recorded on the pedometer, the time activity budgets, and the ADCS data were used to objectively assess the presence/degree of sedation or excitement in the foals.
After collection of the 24-hr blood sample, the cephalic catheter was removed. The foals and their dams were observed for any signs of adverse effects for 24 hr and then were returned to the research herd. After a minimum 5-day, maximum 7-day washout period, the dam and foal were again brought into a stall and the process was repeated with another treatment. Each foal received all three treatments, and the final treatment was administered at or prior to 21 days of age.
| Chromatographic assay for buprenorphine concentrations
Concentrations of buprenorphine and its active metabolite, norbu- . Column temperature was maintained at 30°C and sample temperature was maintained at 4°C. Separation was achieved using an Acquity UPLC HSS T3 column (1.8 μm, 2.1 × 100 mm) and guard column (Waters Corporation, Milford, MA). After the initial foal samples (0.01 mg/kg) were analyzed, the remaining samples from foals dosed at 0.02 mg/kg were run over a five-day period. For each foal, the IV and SL samples were run on an individual day. Standard curves were prepared fresh for each analytical day and were linear over a concentration range of 0.25-100 ng/ml for buprenorphine and 1-100 ng/ml for norbuprenorphine, with an R 2 ≥ 0.99 daily.
The lower limit of quantification (LLOQ) for buprenorphine was 0.25 ng/ml, and the lower limit of detection (LLOD) was 0.1 ng/ml.
All standard concentrations were calculated to within ±15% of the true concentration. For buprenorphine at concentrations of 100, 5
and 0.5 ng/ml, the intraday accuracy was 2.24 ± 1.73% and intraday precision was 2.69 ± 1.65. For norbuprenorphine, the LLOQ was 0.5 ng/ml, and the LLOD was 0.1 ng/ml.
| Pharmacokinetic and statistical analysis 2.2.1 | Pharmacokinetic data
Plasma concentration data were subjected to compartmental modeling as well as noncompartmental analysis using commercially avail- Parameters reported include area under the plasma concentrationversus-time curve extrapolated to infinity (AUC 0-∞ ), absorption and elimination rate constants (k 01 and k 10 , respectively), and half-life of absorption and elimination (t ½ k 01 and t ½ k 10 , respectively). Volume of distribution at steady-state (VD ss ) and clearance (Cl) are reported for the IV data. The maximum concentration (C max ) and time to maximum concentration (T max ) from the sublingual data were taken directly from the data. Bioavailability (F%) of buprenorphine was calculated using the AUC 0-∞ determined from compartmental analysis and the formula F = (AUC SL /AUC IV ) * 100, corrected for dose when appropriate using the equation F = (AUC SL *Dose IV )/(AUC IV *Dose SL ) * 100.
| Physiologic, behavioral, and activity data
Physiologic, behavioral, and activity data from all foals, regardless of buprenorphine dose, were included in the statistical analysis. This decision was prepared because of the small number of foals available and because there were no meaningful changes between the analysis with all foals and that including only foals receiving the higher dose of buprenorphine. Additionally, due to the small numbers, data between the two doses were not compared. Heart rate, respiratory rate, tem- Sequence (i.e., the order of treatment) was not included in the model because only one sequence had more than one foal. Study period treatment was included in the model to adjust for potential differences, and significance was not interpreted. The model also included a random effect for foal nested within sequence and covariance parameters for the repeated measures within a study period. Model assumptions were verified visually using normal probability plots and figures of studentized residuals plotted against predicted values.
In some cases (heart rate, respiratory rate, pedometer reading, and percentage time nursing), a logarithmic transformation was used to insure normality of the residuals. The spatial power covariance structure was selected for each outcome to model the covariance for repeated measures within a study period. This structure was chosen because it had the lowest value of the corrected Akaike Information Criterion (AIC c ). A spatial structure was advantageous because the TA B L E 3 Two-compartmental pharmacokinetic parameters for buprenorphine (0.01-0.02 mg/kg) given intravenously Note. A = coefficient of the distribution phase; α = slope of the distribution phase; B = coefficient of the elimination phase; β = slope of the elimination phase; t 1/2α = half-life of distribution; t 1/2β = half-life of elimination; k 10 = first-order elimination rate constant; k 12 = first-order transfer rate constant describing distribution between the central and peripheral compartments; k 21 = first-order elimination rate constant; k 12 = first-order transfer rate constant describing distribution between the peripheral and central compartments; Vd ss = volume of distribution at steady-state; Cl = systemic clearance; AUC = area under the concentration-time curve; AUMC = area under the first moment-time curve; λ = slope of the terminal phase; t 1/2λ = half-life of terminal phase.
TA B L E 2 Description of data compliance scoring of video recordings of neonatal foals following treatment with 0.01 or 0.02 mg/kg buprenorphine (IV or sublingual) or saline 
| RE SULTS
The foals' age/weight ranged from 4 to 19 days/38.6 to 86.0 kg for SL, 6 to 21 days/47.7 to 66.8 kg for IV, and 6 to 20 days/41.8 to 78.2 kg for C. The oral pH was 8-9 in all foals at all treatments. This is equivalent to oral pH reported in adult horses (Messenger et al., 2011) .
| Plasma buprenorphine concentrations
Pharmacokinetic data for all foals are presented in Tables 3 and   4 The elimination half-life was 1.95 ± 0.7 hr for the IV group 1.16 ± 0.87 hr for the SL group. Plasma buprenorphine concentrations were <0.6 ng/ml in all treated foals by 4 hr postadministration. The active metabolite, norbuprenorphine, was not detected in any sample. Notes. T max = time to maximum concentration; C max = maximum concentration; k 01 = first-order absorption rate constant; k 10 = first-order elimination rate constant; k 01 t 1/2α = half-life of absorption; k 10 t 1/2β = half-life of elimination; AUC 0-∞ = area under the concentration-time curve extrapolated to infinity; F = systemic bioavailability. a Reported directly from the data. b Not reported due to very high clearance following IV administration in this foal, resulting in a bioavailability >100%. SL (145.5, vs. 78.3, , p = 0.008) and C (vs. 26.3, 95% CI: 12.1-57.1, p < 0.0001), and SL was also higher than C (p < 0.0001). The mean percentage of time spent nursing was higher for IV and SL versus C between 120 and 240 min (all p < 0.0001, Table 6 ), and SL was more active than either C or IV, although differences did not achieve statistical significance.
| Physiologic, behavioral, and activity data
The C group was more recumbent on average from 120 to 240 min than both IV and SL (all p < 0.001; Table 7 ). None of these differences were considered to be clinically significant. There were no statistical differences detected between treatments for GI sounds, % inactivity, and ADCS. Signs of excitement, sedation, and colic did not occur in any foal.
| D ISCUSS I ON
In this study, buprenorphine was absorbed following SL administration to neonatal foals but plasma concentrations presumed to provide analgesia in other species (>0.6 ng/ml) were not consistently reached (SL administration) or not consistently sustained (both routes of administration) for the predicted 6 hr. Buprenorphine-mediated F I G U R E 1 Plasma concentration (ng/ml) of buprenorphine following sublingual administration of 0.01 or 0.02 mg/kg buprenorphine to six neonatal foals Notes. Only time points with significant differences are reported. *p < 0.0001 (vs. control).
physiologic and behavior changes were mild and statistically significant but clinically insignificant in this single dose study using healthy nonpainful foals. No foal exhibited excitement, sedation, or signs of colic. Sublingual administration was accomplished easily, and only minimal restraint was required.
Following SL administration, a significant discrepancy in plasma drug concentrations between samples collected from the jugular vein and samples collected from arteries or more peripheral veins has been reported Messenger et al., 2011) . It is likely that systemic buprenorphine concentrations are overestimated with SL drug administration followed by jugular vein sampling as drug absorbed from the buccal mucosa drains directly into the jugular vein prior to being systemically circulated.
Plasma drug concentrations following SL buprenorphine (0.006 mg/ kg) administered to adult horses produced a C max of 8.77 ± 3.19 ng/ ml and bioavailability of >100% in jugular vein samples (Messenger et al., 2011) . However, plasma drug concentrations were below detectable limits at most time points following sampling from the lateral thoracic vein. Blood collected from the cephalic vein, as used in our study, most likely represents whole-body concentrations.
Arterial sampling would also be appropriate; however, the difficulty of obtaining arterial samples in awake, healthy foals outweighed the benefits of this sampling site. The ability to detect buprenorphine plasma concentrations in peripheral veins following SL administration in the foals of the present study but not following SL administration in adult horses (Messenger et al., 2011 ) may be due to a variety of reasons. Higher bioavailability and greater absorption may occur in neonatal foals compared to adults. Alternatively, the higher dose used in our study or the lower total blood volume in the foals, which equates to decreased dilution after absorption, may have influenced plasma concentrations. There are no studies comparing lateral thoracic vein drug concentrations to cephalic drug concentrations, so it is also possible that the sample site differences played a role.
The original study dose of 0.01 mg/kg buprenorphine was based on the IM dose shown to provide analgesia in similarly aged foals (Risberg et al., 2015) . Despite the dose increase to 0.02 mg/kg, the target plasma concentration that provides analgesia in other species was not achieved in five foals of the SL group and was not sustained at the target plasma concentration for the expected duration (>6 hr) in either treatment group. This is different from adult horses where, following buprenorphine administration of 0.005 mg/kg IV or IM, plasma concentrations were above 0.6 ng/ml for approximately 8 and 12 hr, respectively, and were above the limit of quantification (0.1 ng/ml) for at least 24 hr (the last sampling time) in either dose group (Davis et al., 2012) . Following administration of 0.006 mg/kg buprenorphine IV, the drug was quantifiable in plasma for ≥8 hr in four of five horses and still detectable at 24 hr (last sampling point)
in two of five horses (Messenger et al., 2011) . In a more recent study, following IV administration of 0.01 mg/kg IV, plasma buprenorphine concentrations were quantifiable for a shorter time (up to 8 hr in four horses and up to 12 hr in two horses; Love et al., 2015) than previously reported, but still longer than was quantifiable in our foals. This is likely due to pharmacokinetic differences between foals and adult horses following IV administration of buprenorphine (Davis et al., 2012; Love et al., 2015; Messenger et al., 2011) . In the present study, mean t 1/2β was 1.95 hr, which is much shorter than the in t 1/2λ reported in adult horses (3.58-5.79 hr) (Davis et al., 2012; Messenger et al., 2011) . Differences were also noted in both the VD ss and Cl between the two age groups. In the present study, foals had a larger VD ss (6.46 L/kg) and more rapid Cl (55.83 ml/kg/min) when compared to the same indices in adult horses (3.01-3.16 L/ kg and 6.13-7.97 ml/kg/min; Davis et al., 2012; Messenger et al., 2011) . The relationship between VD and Cl with respect to half-life can be summarized in the equation t 1/2 = (0.693*VD)/Cl. Therefore, although the VD ss in neonatal foals was approximately double that in adult horses, this was offset by the much higher clearance values, resulting in a shorter half-life.
Factors that should be considered as a possible cause of an increased VD include differences in plasma protein binding and a more permeable blood-brain barrier. Buprenorphine is highly protein bound in humans (96%; Elkader & Sproule, 2005) and the lower plasma protein seen in neonates may affect the unbound portion, which is free to distribute to tissues.
Changes in clearance are also not unexpected; however, with many drugs, it is assumed that neonates will have a stunted metabolism and elimination of drugs, and therefore a decreased clearance compared to adults. This is not the case for all drugs, however, and similar findings of a faster clearance have been noted with butorphanol in neonatal foals (Arguedas et al., 2008) . A faster clearance of buprenorphine has also been documented in children following IV dosing (Olkkola, Maunuksela, & Korpela, 1989) , with the difference potentially due to a higher ratio of hepatic weight to body weight in children. The exact mechanism for an increased clearance cannot be determined from the present study, as the metabolic and elimination pathways of buprenorphine in the horse are not well defined. Norbuprenorphine, the primary active metabolite seen in humans, has not been detected in either neonatal or adult horses. Buprenorphine bioavailability following SL administration of 0.02 mg/kg to five foals was 25.1 ± 10.9%. There are no SL bioavailability data published in neonates of any veterinary species for comparison. Bioavailability could not be determined in adult horses due to low to undetectable plasma concentrations following SL administration (Messenger et al., 2011) . Bioavailability data following SL administration in other adult veterinary species were mostly reported following jugular vein sampling (Abbo et al., 2008; Krotscheck et al., 2010; Porters et al., 2015; Robertson et al., 2003 Robertson et al., , 2005 . In two studies involving adult cats receiving SL buprenorphine, bioavailability calculated from blood sampled from the carotid artery and medial saphenous vein was 32% and 23%, respectively and 24% from blood sampled from a central vein (Doodnaught et al., 2017) , compared to 116% from jugular vein samples (Robertson et al., 2003) . In adult humans, buprenorphine bioavailability following SL administration of 2 mg/adult volunteer was approximately 30% (Kuhlman et al., 1996) . Sampling was from the antecubital vein.
Pharmacodynamically, signs of mild stimulation (tachypnea, tachycardia, increased body temperature, increased time spent nursing, and decreased time spent recumbent (Tables 5-7 ), but not overt excitement, occurred in both buprenorphine groups at various time points. All signs were statistically but not clinically significant as determined by the fact that the changes were not outside the limits of normal values in neotatal foals. These changes are likely due to the stimulatory central nervous system effects of opioids in horses.
Tachypnea and increased motor activity occurred in foals receiving IM buprenorphine (Risberg et al., 2015) . Increased body temperature and increased time spent nursing occurred in foals receiving IM butorphanol (Arguedas et al., 2008) .
It is possible that some of the physiologic variables could have changed for nonopioid related reasons. In particular, RR and body temperature could have increased because of ambient heat but daily ambient temperature in the research barn was not correlated with changes in RR or body temperature. The increases could also have been caused by stress from restraint during data collection, but all foals were handled the same and RR and body temperature were only elevated in the treatment groups. In addition, an increase in HR would have been expected if the changes were stress-related.
Also, the highest buprenorphine plasma concentration occurred at the first sampling time after IV administration and at approximately 1 hr following SL administration (Figures 1 and 2 ) yet many of the physiologic changes occurred 2-4 hr after administration (Tables 5-7) , which fits with buprenorphine binding kinetics. Buprenorphine, compared to other opioids like fentanyl, has a much slower binding time to and longer dissociation from the opioid receptor (Boas & Villiger, 1985) .
The lack of analgesic testing is a limitation of this study. Although the onset of opioid-mediated physiologic changes might signal the onset of opioid-mediated analgesia, opioid-mediated physiologic changes (mydriasis, euphoria, sedation) without analgesia have been reported in cats (Murrell et al., 2007) . Thus, it is possible that the physiologic changes do not predict analgesia. However, it is also possible that, because buprenorphine effects are not related to plasma concentration but to receptor binding kinetics, the low plasma concentrations do not rule out an analgesic effect (Olkkola et al., 1989) . In adult horses, thermal thresholds were increased for 8-12 hr in spite of plasma buprenorphine concentrations above 0.6 ng/ml for only 4 hr in four of six horses (Love et al., 2015) . The plasma concentration range that provided analgesia in response to a thermal threshold research stimulus was 0.34-2.45 ng/ml. Had 0.3 ng/ml been the potential analgesic threshold in this study, all of the foals in both groups would have achieved plasma concentrations above the presumed threshold, and three foals in the IV group would have sustained those concentrations for 4-6 hr, but no change in sustainability in the SL group. It is possible that the low plasma buprenorphine concentrations in the foals would have produced analgesia along with the production of the measured physiologic and behavior changes. Similar changes occurred in conjunction with analgesia in neonatal foals receiving buprenorphine IM at the low dose used in three of our foals (0.01 mg/kg; Risberg et al., 2015) .
Gastrointestinal sounds were present at all times in all foals. In other studies, GI sounds were decreased in treatment groups but no signs of abdominal pain occurred (Davis et al., 2012; Messenger et al., 2011) . In a different study, only one horse had decreased GI sounds at one time point, but all horses had normal fecal production and no signs of colic (Love et al., 2015) . Abnormalities in GI motility
were not reported in the study in which foals received IM buprenorphine (Risberg et al., 2015) . Monitoring GI sounds is often used as an estimation of GI motility, but the presence of GI sounds does not rule out decreased motility. In addition to signs of abdominal pain, measuring fecal output (timing and volume) would have been beneficial in this study.
Limitations of this study include the fact that only six foals were utilized, and all foals were healthy, nonpainful and either Arabian or Arabian/pony crosses. Genetic variation of opioid metabolism has been identified in other species (Somogyi, Barratt, & Coller, 2007) . A larger cohort would have also allowed removal of the data from the three foals receiving 0.01 mg/kg buprenorphine, which may have changed results slightly, but likely not significantly. The data pool was too small to allow for comparison of the pharmacokinetic parameters following the two dosages; however, individual foal data, including dosages, are represented in Figures 1 and 2 . The use of behavior analysis as a major component of the study could be a limitation as behavior changes can be very subjective. Attempts to standardize the analysis include characterization of discreet behaviors for assessment, assessment of behavior from video footage so that foals could be watched without human interaction or presence and the use of 3-trained, blinded observers to score the videos.
Pedometer data were not collected prior to initiation of the study, and some foals may have been normally more active than others.
Additionally, the pedometer was not calibrated for foals and may not have counted the right number of steps. However, if the pedometer did miscount, all foals should have been impacted equally, creating a constant bias in both groups. In addition, as this was a single-dose study, any cumulative effect could not be determined. Physiologic changes that were not clinically significant or detrimental in this study could be clinically relevant in a foal dosed multiple times daily or receiving an infusion. Finally, not including analgesic assessment in the study limits the clinical applicability of the dosages studied but determining an appropriate dose to test is a valid first step in pharmacokinetic/pharmacodynamics research.
In conclusion, buprenorphine can easily be administered SL to neonatal foals. Buprenorphine at a dose of 0.02 mg/kg causes mild, clinically insignificant changes in physiologic parameters, behavior, and activity data, despite low plasma concentrations. Further studies should be performed to determine whether buprenorphine administered by this route provides analgesia. Buprenorphine pharmacokinetics were different in neonatal foals than those reported in adult horses, which emphasizes the need to perform dosing studies in each age group expected to receive a drug.
